Search research articles
Contact Us
Filters
Showing results (1-10 of 18) with videos related to
Page
of 2
Sort By:
Advanced Drug Delivery Reviews
|
November 8, 2005
Microdialysis assessment of drug delivery systems for vitreoretinal targets
Sridhar Duvvuri, Kay D Rittenhouse, Ashim K Mitra
Translational Vision Science & Technology
|
May 16, 2023
Aflibercept Suppression of Angiopoietin-2 in a Rabbit Retinal Vascular Hyperpermeability Model
Claudia Lange, Reimo Tetzner, Tobias Strunz, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
|
February 7, 2012
Retina expression and cross-species validation of gene silencing by PF-655, a small interfering RNA against RTP801 for the treatment of ocular disease
Dong U Lee, Wenhu Huang, Kay D Rittenhouse, et al.
Translational Vision Science & Technology
|
May 18, 2021
Durability of VEGF Suppression With Intravitreal Aflibercept and Brolucizumab: Using Pharmacokinetic Modeling to Understand Clinical Outcomes
Thomas Eissing, Michael W Stewart, Cynthia X Qian, et al.
Translational Vision Science & Technology
|
October 25, 2022
Evaluation of Molecular Properties versus In Vivo Performance of Aflibercept, Brolucizumab, and Ranibizumab in a Retinal Vascular Hyperpermeability Model
William Schubert, Carsten Terjung, Ashique Rafique, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
|
July 29, 2004
Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period
Jean-Yves Driot, Gary D Novack, Kay D Rittenhouse, et al.
Investigative Ophthalmology & Visual Science
|
June 15, 2012
Evaluations of tear protein markers in dry eye disease: repeatability of measurement and correlation with disease
Jing-Feng Huang, Yi Zhang, Kay D Rittenhouse, et al.
Neurochemistry International
|
June 16, 2009
The localization of PGE2 receptor subtypes in rat retinal cultures and the neuroprotective effect of the EP2 agonist butaprost
Belmira Lara da Silveira Andrade da Costa, Kui Dong Kang, Kay D Rittenhouse, et al.
Ophthalmology and Therapy
|
November 4, 2023
Real-World Management of Macular Edema Secondary to Retinal Vein Occlusion with Intravitreal Aflibercept: 24-month Results from the AURIGA Observational Study
Audrey Giocanti-Aurégan, Simone Donati, Hans Hoerauf, et al.
Investigative Ophthalmology & Visual Science
|
July 9, 2024
ANO2 Genetic Variants and Anti-VEGF Treatment Response in Neovascular AMD: A Pharmacogenetic Substudy of VIEW 1 and VIEW 2
Robyn H Guymer, Rufino Silva, Mercedeh Ghadessi, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 18) with videos related to
Sort By:
Page
of 2
Advanced Drug Delivery Reviews
|
November 8, 2005
Microdialysis assessment of drug delivery systems for vitreoretinal targets
Sridhar Duvvuri, Kay D Rittenhouse, Ashim K Mitra
Translational Vision Science & Technology
|
May 16, 2023
Aflibercept Suppression of Angiopoietin-2 in a Rabbit Retinal Vascular Hyperpermeability Model
Claudia Lange, Reimo Tetzner, Tobias Strunz, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
|
February 7, 2012
Retina expression and cross-species validation of gene silencing by PF-655, a small interfering RNA against RTP801 for the treatment of ocular disease
Dong U Lee, Wenhu Huang, Kay D Rittenhouse, et al.
Translational Vision Science & Technology
|
May 18, 2021
Durability of VEGF Suppression With Intravitreal Aflibercept and Brolucizumab: Using Pharmacokinetic Modeling to Understand Clinical Outcomes
Thomas Eissing, Michael W Stewart, Cynthia X Qian, et al.
Translational Vision Science & Technology
|
October 25, 2022
Evaluation of Molecular Properties versus In Vivo Performance of Aflibercept, Brolucizumab, and Ranibizumab in a Retinal Vascular Hyperpermeability Model
William Schubert, Carsten Terjung, Ashique Rafique, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
|
July 29, 2004
Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period
Jean-Yves Driot, Gary D Novack, Kay D Rittenhouse, et al.
Investigative Ophthalmology & Visual Science
|
June 15, 2012
Evaluations of tear protein markers in dry eye disease: repeatability of measurement and correlation with disease
Jing-Feng Huang, Yi Zhang, Kay D Rittenhouse, et al.
Neurochemistry International
|
June 16, 2009
The localization of PGE2 receptor subtypes in rat retinal cultures and the neuroprotective effect of the EP2 agonist butaprost
Belmira Lara da Silveira Andrade da Costa, Kui Dong Kang, Kay D Rittenhouse, et al.
Ophthalmology and Therapy
|
November 4, 2023
Real-World Management of Macular Edema Secondary to Retinal Vein Occlusion with Intravitreal Aflibercept: 24-month Results from the AURIGA Observational Study
Audrey Giocanti-Aurégan, Simone Donati, Hans Hoerauf, et al.
Investigative Ophthalmology & Visual Science
|
July 9, 2024
ANO2 Genetic Variants and Anti-VEGF Treatment Response in Neovascular AMD: A Pharmacogenetic Substudy of VIEW 1 and VIEW 2
Robyn H Guymer, Rufino Silva, Mercedeh Ghadessi, et al.
Page
of 2